Financial Performance - Adjusted net profit for 2024 increased by 139% compared to 2023, benefiting from enhanced technology and improved operational efficiency [4]. - Total revenue for the year reached RMB 2.707 billion, reflecting an 11.2% increase compared to RMB 2.434 billion in 2023 [6][11]. - The company achieved a pre-tax loss of RMB 854.853 million for the year, compared to a loss of RMB 196.711 million in 2023 [6]. - Total comprehensive loss increased from RMB 1,968 million for the year ending December 31, 2023, to RMB 8,549 million for the year ending December 31, 2024 [45]. - Adjusted net profit for the year ending December 31, 2024, was RMB 17.1 million, compared to RMB 7.2 million for the year ending December 31, 2023 [50]. - Operating loss for the year was RMB 777,693,000, significantly higher than the operating loss of RMB 51,895,000 in the previous year [94]. - The company reported a net loss of RMB 854,885,000 attributable to ordinary equity shareholders in 2024, compared to a loss of RMB 196,788,000 in 2023 [124]. User Engagement and Growth - As of December 31, 2024, the platform registered users grew to 49.2 million, with an average monthly active user count of 10.1 million, representing a 20% year-over-year increase [4][11]. - The repeat purchase rate for paying users remained strong at 84.7% for the year ended December 31, 2024 [11]. - The company plans to expand its market presence and enhance its product offerings through ongoing research and development initiatives [144]. - The company plans to strengthen its online chronic disease management market leadership by balancing immediate tactical improvements with long-term strategic planning [22]. Revenue Streams - Online retail pharmacy service revenue increased by 8.3% from RMB 1,297.1 million for the year ended December 31, 2023, to RMB 1,404.8 million for the year ended December 31, 2024 [16]. - Revenue from integrated medical services decreased by 34.3% from RMB 983.7 million for the year ended December 31, 2023, to RMB 646.5 million for the year ended December 31, 2024, with a focus on enhancing profitability and sustainable development [30]. - Wholesale revenue surged by 728.5% from RMB 66.5 million for the year ended December 31, 2023, to RMB 550.9 million for the year ended December 31, 2024, leveraging long-term supply chain relationships [31]. - Revenue from customized content and marketing solutions rose by 20.7% from RMB 87.0 million for the year ended December 31, 2023, to RMB 105.1 million for the year ended December 31, 2024, due to improved recognition and outreach efforts [32]. Operational Efficiency - The company focused on developing and integrating emerging technologies, including AI, big data, and cloud computing, to improve platform functionality and user experience [14]. - Inventory turnover days improved from 24.6 days for the year ended December 31, 2023, to 23.1 days for the year ended December 31, 2024 [19]. - Total sales costs increased by 12.6% to RMB 2,191.4 million for the year ended December 31, 2024, from RMB 1,946.9 million for the year ended December 31, 2023, aligning with revenue growth [34]. - Gross profit increased by 5.9% from RMB 487.4 million for the year ended December 31, 2023, to RMB 515.9 million for the year ended December 31, 2024, while overall gross margin decreased to 19.1% [35]. Assets and Liabilities - Non-current assets as of December 31, 2024, amounted to RMB 55.769 million, while current assets totaled RMB 608.325 million [7]. - Trade receivables rose from RMB 241 million as of December 31, 2023, to RMB 363 million as of December 31, 2024 [54]. - Cash and cash equivalents increased from RMB 146.3 million as of December 31, 2023, to RMB 174.6 million as of December 31, 2024, indicating improved cash flow from operating activities [58]. - Total trade and other payables increased to RMB 457,497 thousand in 2024 from RMB 440,451 thousand in 2023, with trade payables rising to RMB 348,627 thousand from RMB 292,944 thousand [134]. Strategic Initiatives - The company plans to allocate RMB 10.73 million (16.0%) of its funds for research and development activities by December 2028 [84]. - A team of approximately 40 software engineers will be hired, with 70% being senior engineers, to enhance AI and big data capabilities in chronic disease management by December 2028 [84]. - The company aims to optimize its infrastructure across various technology domains, including computer vision and natural language processing, to improve user experience and system stability by December 2028 [84]. - The company plans to expand its product range and improve supply chain capabilities with 5.5% of the net proceeds, which is HKD 3.69 million [82]. Governance and Compliance - The board of directors consists of an executive chairman, two executive directors, and several independent non-executive directors, ensuring a diverse governance structure [155]. - The audit committee has reviewed the financial statements and confirmed compliance with applicable accounting standards and regulations [87]. - The company has no significant litigation or arbitration cases as of December 31, 2024 [90]. Capital and Funding - The net proceeds from the global offering amount to approximately HKD 67.09 million, which will be allocated according to the disclosed purposes in the prospectus [80]. - 67.4% of the net proceeds will be used for business expansion, with HKD 45.22 million allocated for this purpose [82]. - The expected timeline for utilizing the net proceeds is by December 2028 [82].

Group 1 - Ark Health (06086) saw a significant stock increase of over 17%, currently trading at 5.77 HKD with a transaction volume of 138 million HKD [1] - The company recently announced the integration of DeepSeek's open-source large model, completing private deployment, which enhances the digital drive for "AI + chronic disease management" [1][2] - Ark Health aims to develop multiple "AI intelligent assistant" scenarios by 2025, increasing R&D investment to leverage advanced models like DeepSeek for extracting medical data value [2] Group 2 - The launch of the first fully domestic intelligent solution in the medical industry, "Bianshi + DeepSeek dual-engine medical intelligent machine," was a collaborative effort with Huawei [1] - The company is focusing on creating a "H2H (Hospital To Home) smart medical ecosystem" to upgrade its "AI + H2H" strategy, positioning it as a new growth point for its smart medical business [1] - Ark Health has recently been included in the Hong Kong Stock Connect list and is set to release its 2024 annual performance report [2]

Revenue Growth - Fangzhou Inc. reported a revenue increase of 131% for the interim period ending June 30, 2024, compared to the previous year[1]. - The company anticipates a revenue guidance of $50 million for the next fiscal year, representing a 20% increase from the current year[1]. - Revenue for the six months ended June 30, 2024, was RMB 1,322,821 thousand, a 2.5% increase from RMB 1,291,014 thousand in the same period of 2023[7]. - Total revenue for the six months ended June 30, 2024, was RMB 1,322.8 million, a 2.5% increase from RMB 1,291.0 million for the same period in 2023[19]. - Online retail pharmacy service revenue increased by 9.6% from RMB 614.7 million to RMB 673.7 million, driven by increased sales of pharmaceuticals and health products[20]. - Wholesale revenue surged by 842.1% from RMB 29.6 million to RMB 278.9 million, leveraging established supply chain relationships[22]. - Customized content and marketing solutions revenue rose by 42.3% from RMB 34.7 million to RMB 49.4 million, due to ongoing marketing initiatives targeting more corporate clients[23]. User Engagement and Growth - The company achieved a monthly active user count of 1.5 million, reflecting a growth of 25% year-over-year[3]. - As of June 30, 2024, the platform had 45.6 million registered users and nearly 217,000 registered doctors, indicating significant user growth[9]. - The average monthly active users on the platform reached 8.9 million, demonstrating sustained user engagement[11]. - The repeat purchase rate for paid users was strong at 85.8%, showcasing user loyalty and platform stickiness[11]. - Fangzhou Inc. is focused on improving user engagement through targeted marketing campaigns, expecting a 15% increase in user retention rates[3]. Financial Performance - Adjusted net profit for the first half of 2024 increased by 395.0% compared to the same period in 2023, attributed to enhanced technology utilization[9]. - Gross profit for the same period was RMB 265,549 thousand, up from RMB 247,005 thousand, reflecting improved operational efficiency[7]. - The company reported a pre-tax loss of RMB 818,707 thousand for the first half of 2024, compared to a loss of RMB 153,834 thousand in the same period of 2023[7]. - The total comprehensive loss increased from RMB 153.9 million for the six months ended June 30, 2023, to RMB 818.7 million for the same period in 2024[30]. - The net loss for the six months ended June 30, 2024, was RMB 818,725 thousand, compared to a loss of RMB 42,892 thousand for the same period in 2023[90]. - The operating loss for the six months ended June 30, 2024, was RMB 746,258 thousand, compared to RMB 80,800 thousand in the previous year, reflecting a significant increase in losses[85]. Strategic Initiatives - Fangzhou Inc. plans to expand its market presence by launching new healthcare services and enhancing its H2H service platform in the next quarter[2]. - The company is exploring potential acquisitions to enhance its service offerings and market reach[2]. - The company has established strategic partnerships with three major hospitals to enhance its service delivery[2]. - The company aims to increase its product SKU count by 30% in the upcoming year to diversify its offerings[4]. - The company plans to enhance doctor-patient connections and user engagement by expanding its doctor operation team and introducing AI service tools[15]. Research and Development - The company has allocated $10 million for research and development of new technologies aimed at chronic disease management[1]. - The company will continue to attract top talent in AI, healthcare, chronic disease management, and the pharmaceutical industry to support ongoing development[16]. - A total of HKD 10.73 million (16.0%) is allocated for R&D activities, with a focus on hiring a team of approximately 40 software engineers by 2028[65]. Financial Position and Liabilities - Non-current assets were RMB 59,493 thousand, while current assets were RMB 512,728 thousand as of June 30, 2024[8]. - Net liabilities increased to RMB (1,988,601) thousand as of June 30, 2024, compared to RMB (1,901,463) thousand at the end of 2023[8]. - Total liabilities as of June 30, 2024, were RMB 2,028,184 thousand, compared to RMB 1,940,889 thousand at the end of 2023, indicating an increase of 4.5%[88]. - The company’s total liabilities as of June 30, 2024, were RMB 480,623 million, up from RMB 440,451 million as of December 31, 2023, indicating a rise of approximately 9.1%[121]. Shareholder Information - As of June 30, 2024, the total number of shares issued is 1,340,267,457, with Mr. Xie holding 20.64% and Mr. Zhou holding 17.65% of the shares[58]. - The company has not utilized any net proceeds from the global offering since its listing on July 9, 2024, with an expected utilization of approximately HKD 10.0 million to HKD 20.0 million by December 31, 2024, representing about 14.9% to 29.8% of the net proceeds[64]. - The company has issued 3,500,000 and 20,000,000 restricted shares to Mr. Zou and Torano Investments Limited, respectively, under the restricted share unit plan[58]. - The company has a total of 116,875,898 shares allocated for the restricted share unit plan for directors and senior management[60]. Operational Efficiency - Fangzhou Inc. reported a gross margin of 45%, indicating strong operational efficiency[1]. - The gross profit increased by 7.5% from RMB 247.0 million for the six months ended June 30, 2023, to RMB 265.5 million for the same period in 2024, with an overall gross margin improvement to 20.1% from 19.1%[25]. - The company has implemented an online medical insurance payment system to facilitate convenient online payments for chronic disease patients[12].

Financial Performance - The adjusted net profit of the company for the first half of 2024 increased by 395.0% compared to the same period in 2023, attributed to enhanced operational efficiency through technology[1]. - Revenue for the six months ended June 30, 2024, was RMB 1,322,821,000, a slight increase from RMB 1,291,014,000 in the same period of 2023[2]. - The gross profit for the first half of 2024 was RMB 265,549,000, compared to RMB 247,005,000 in the previous year[2]. - Revenue for the six months ended June 30, 2024, increased by 2.5% to RMB 1,322.8 million from RMB 1,291.0 million for the same period in 2023, primarily driven by growth in online retail pharmacy services, wholesale, and customized content and marketing solutions[10]. - Gross profit for the six months ended June 30, 2024, increased by 7.5% to RMB 265.5 million, with an overall gross margin of 20.1%, up from 19.1% in the prior year[18]. - The total loss and comprehensive income for the six months ended June 30, 2024, increased to RMB 818.7 million from RMB 153.9 million for the same period in 2023[25]. - Adjusted net profit for the six months ended June 30, 2024, was RMB 15.1 million, compared to RMB 3.0 million for the same period in 2023, with an adjusted net profit margin of 1.1% versus 0.2%[26]. - The company reported a loss attributable to equity shareholders of RMB 818,725 thousand, compared to a loss of RMB 153,896 thousand in the prior year[59]. - The group reported a net loss before tax of RMB 818,707,000 for the six months ended June 30, 2024, compared to a net loss of RMB 153,834,000 for the same period in 2023[74]. User Engagement and Growth - As of June 30, 2024, the company had 45.6 million registered users and nearly 217,000 registered doctors, collaborating with over 1,500 suppliers and more than 800 pharmaceutical companies[1]. - The company achieved a strong repeat purchase rate of 85.8% for paid users as of June 30, 2024, indicating high user loyalty and platform stickiness[5]. - The average monthly active users on the company's platform reached 8.9 million for the twelve months ending June 30, 2024, reflecting sustained user engagement[4]. - Online retail pharmacy services revenue rose by 9.6% to RMB 673.7 million, accounting for 50.9% of total revenue, benefiting from increased sales volume and user growth[12]. Revenue Breakdown - Prescription drug transaction volume accounted for 81.8% of the total transaction volume during the reporting period, consistent with previous periods[5]. - Integrated medical services revenue decreased by 47.6% to RMB 320.7 million, representing 24.2% of total revenue, as the company shifted focus towards profitability and sustainable growth[13]. - Wholesale revenue surged by 842.1% to RMB 278.9 million, making up 21.1% of total revenue, leveraging established supply chain relationships[14]. - Customized content and marketing solutions revenue increased by 42.3% to RMB 49.4 million, driven by ongoing marketing initiatives to expand the customer base[15]. Operational Efficiency and Strategy - The company successfully implemented an online medical insurance payment system for outpatient services, enhancing convenience for chronic disease patients[5]. - The online retail pharmacy service launched an instant settlement feature for dual-channel prescription drugs, improving service for chronic disease patients[6]. - The company plans to enhance doctor-patient connections and user engagement by expanding its doctor operations team and introducing AI service tools[8]. - The company aims to strengthen its supply chain and expand product offerings to meet diverse user needs across various medical specialties[9]. - The recruitment strategy focuses on attracting top talent in AI, healthcare, chronic disease management, and pharmaceuticals to support ongoing development[9]. Expenses and Financial Position - Sales and distribution expenses for the six months ended June 30, 2024, were RMB 171.1 million, slightly down from RMB 175.9 million for the same period in 2023, representing 12.9% of revenue compared to 13.6% in the prior year[21]. - Administrative expenses surged by 840.8% to RMB 831.1 million for the six months ended June 30, 2024, from RMB 88.3 million in the same period of 2023, accounting for 62.8% of revenue, up from 6.8%[23]. - Financing costs were relatively stable at RMB 72.4 million for the six months ended June 30, 2024, compared to RMB 73.0 million for the same period in 2023[25]. - The increase in administrative expenses was primarily due to costs associated with the restricted share unit plan[23]. Assets and Liabilities - Cash and cash equivalents were RMB 1,384 million as of June 30, 2024, down from RMB 1,463 million as of December 31, 2023, indicating a slight decrease in liquidity[35]. - Trade receivables remained stable at RMB 279 million as of June 30, 2024, compared to RMB 241 million as of December 31, 2023, reflecting business volume provided to corporate clients[30]. - Other receivables increased from RMB 770 million as of December 31, 2023, to RMB 972 million as of June 30, 2024, mainly due to increased refunds from upstream suppliers related to procurement returns[30]. - Trade and other payables increased from RMB 4,405 million as of December 31, 2023, to RMB 4,806 million as of June 30, 2024, primarily due to business scale growth[33]. - The redeemable preferred shares' liability increased to RMB 1,995,190 thousand as of June 30, 2024, from RMB 1,911,521 thousand as of December 31, 2023[90]. Capital and Investments - The company had no significant investments or acquisitions during the six months ended June 30, 2024, and has no plans for major capital asset acquisitions[43][44]. - The net proceeds from the global offering amounted to approximately HKD 67.09 million, with about 67.4% allocated for business expansion over the next three to five years[53]. - Approximately 17.3% of the proceeds will be used to enhance brand awareness, while 21.5% is aimed at promoting user growth and engagement[53]. - About 16.0% of the proceeds will be dedicated to research and development activities over the next five years[54]. Corporate Governance and Compliance - The audit committee, consisting of three independent non-executive directors, has reviewed the interim results for the six months ending June 30, 2024[57]. - The company has adopted a restricted share unit plan to incentivize employees, with performance evaluations conducted annually[49]. - The company did not declare an interim dividend for the six months ended June 30, 2024[58]. - There were no significant lawsuits or arbitration cases reported during the period[58]. - The company has appointed a new joint company secretary effective August 28, 2024, following a resignation[58].